• A 49-year-old patient with rheumatoid arthritis comes into the clinic with a chief complaint of a fever.
• Patient’s current medications include atorvastatin 40 mg at night, methotrexate 10 mg po every Friday morning and prednisone 5 mg po qam.
• He states that he has had a fever up to 101 degrees F for about a week and admits to chills and sweats.
• He says he has had more fatigue than usual and reports some chest pain associated with coughing.
• He admits to having occasional episodes of hemoptysis.
• He works as a grain inspector at a large farm cooperative.
• After extensive work-up, the patient was diagnosed with Invasive aspergillosis.

ANSWER

 Invasive Aspergillosis in a Patient with Rheumatoid Arthritis: A Clinical Case Study

Introduction

Invasive aspergillosis is a severe fungal infection caused by the Aspergillus species, most commonly Aspergillus fumigatus. This case study explores the presentation, diagnosis, and management of invasive aspergillosis in a 49-year-old patient with rheumatoid arthritis, shedding light on the complexities of diagnosing and treating fungal infections in immunocompromised individuals.

Case Presentation

A 49-year-old patient with a known history of rheumatoid arthritis presented to the clinic with a chief complaint of fever, chills, sweats, and increased fatigue. The patient’s medical history was notable for the use of atorvastatin, methotrexate, and prednisone, medications commonly prescribed for rheumatoid arthritis management. He had been experiencing a fever of up to 101 degrees Fahrenheit for about a week, accompanied by episodes of chills and sweats. Additionally, the patient reported chest pain associated with coughing and occasional episodes of hemoptysis. He was employed as a grain inspector at a large farm cooperative.

Diagnosis: Invasive Aspergillosis

The patient’s clinical presentation, including fever, cough, hemoptysis, and chest pain, raised concerns about a potential respiratory infection. Given his immunocompromised status due to rheumatoid arthritis and the immunosuppressive effects of methotrexate and prednisone, the healthcare team initiated an extensive work-up to identify the underlying cause of his symptoms.

Key Diagnostic Steps

1. Imaging: Chest X-rays and computed tomography (CT) scans revealed the presence of pulmonary infiltrates and nodules, consistent with fungal lung infections.

2. Laboratory Tests: Blood tests, including a complete blood count and fungal culture, were performed to assess for signs of infection. Elevated levels of inflammatory markers and positive fungal cultures indicated a fungal etiology.

3. Bronchoscopy and Biopsy: A bronchoscopy with bronchoalveolar lavage (BAL) and biopsy of lung tissue were conducted to obtain samples for fungal culture and histopathological examination. These tests provided definitive evidence of Aspergillus infection.

Management

Upon confirming the diagnosis of invasive aspergillosis, the patient was promptly initiated on antifungal therapy, specifically voriconazole, which is the first-line treatment for this condition. The management plan also included close monitoring of the patient’s respiratory status and clinical response to treatment.

Discussion

Invasive aspergillosis is a life-threatening fungal infection that primarily affects immunocompromised individuals, making patients with conditions like rheumatoid arthritis, who often receive immunosuppressive medications, particularly vulnerable. The presentation of fever, cough, chest pain, and hemoptysis is concerning and should prompt a comprehensive diagnostic work-up.

Conclusion

This case study highlights the importance of considering invasive fungal infections, such as aspergillosis, in the differential diagnosis of immunocompromised patients presenting with respiratory symptoms. Early diagnosis and appropriate antifungal therapy are crucial for improving outcomes in individuals with invasive aspergillosis. Healthcare professionals must maintain a high index of suspicion for fungal infections, especially in patients receiving immunosuppressive therapies, to ensure timely intervention and effective management.